Lucy Therapeutics

Lucy Therapeutics

Biotechnology, Ne 53rd St, Waltham, , 98662, Massachusetts, 10455, United States, 51-200 Employees

lucytherapeutics.com

  • twitter
  • LinkedIn

phone no Phone Number: 17*********

Who is LUCY THERAPEUTICS

Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTxs unique approach recognizes that...

Read More

map
  • 10455 Ne 53rd St, Waltham, Massachusetts, 98662, United States Headquarters: 10455 Ne 53rd St, Waltham, Massachusetts, 98662, United States
  • 2017 Date Founded: 2017
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5511

checked-icon Does something look wrong? Fix it. | View contact records from LUCY THERAPEUTICS

Lucy Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Lucy Therapeutics

Answer: Lucy Therapeutics's headquarters are located at Ne 53rd St, Waltham, , 98662, Massachusetts, 10455, United States

Answer: Lucy Therapeutics's phone number is 17*********

Answer: Lucy Therapeutics's official website is https://lucytherapeutics.com

Answer: Lucy Therapeutics's revenue is $10 Million to $25 Million

Answer: Lucy Therapeutics's SIC: 5511

Answer: Lucy Therapeutics has 51-200 employees

Answer: Lucy Therapeutics is in Biotechnology

Answer: Lucy Therapeutics contact info: Phone number: 17********* Website: https://lucytherapeutics.com

Answer: Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTxs unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinsons and other CNS diseases.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access